

### Sussex Research

## CD4+ T-cell count at antiretroviral therapy initiation in the "treat all" era in rural South Africa: an interrupted time series analysis

H Manisha Yapa, Hae-Young Kim, Kathy Petoumenos, Frank A Post, Awachana Jiamsakul, Jan-Walter De Neve, Frank Tanser, Collins Iwuji, Kathy Baisley, Maryam Shahmanesh, Deenan Pillay, Mark J Siedner, Till Bärnighausen, Jacob Bor

#### **Publication date**

10-06-2023

#### Licence

This work is made available under the Copyright not evaluated licence and should only be used in accordance with that licence. For more information on the specific terms, consult the repository record for this item.

#### **Document Version**

Accepted version

#### Citation for this work (American Psychological Association 7th edition)

Yapa, H. M., Kim, H.-Y., Petoumenos, K., Post, F. A., Jiamsakul, A., De Neve, J.-W., Tanser, F., Iwuji, C., Baisley, K., Shahmanesh, M., Pillay, D., Siedner, M. J., Bärnighausen, T., & Bor, J. (2021). *CD4+ T-cell count at antiretroviral therapy initiation in the "treat all" era in rural South Africa: an interrupted time series analysis* (Version 1). University of Sussex. https://hdl.handle.net/10779/uos.23483396.v1

#### Published in

Clinical Infectious Diseases

#### Link to external publisher version

https://doi.org/10.1093/cid/ciab650

#### Copyright and reuse:

This work was downloaded from Sussex Research Open (SRO). This document is made available in line with publisher policy and may differ from the published version. Please cite the published version where possible. Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners unless otherwise stated. For more information on this work, SRO or to report an issue, you can contact the repository administrators at sro@sussex.ac.uk. Discover more of the University's research at https://sussex.figshare.com/

Supplementary File.

# CD4+ T-cell count at antiretroviral therapy initiation in the "treat all" era in rural South Africa: an interrupted time series analysis

This file contains the following information:

- Additional Methods
- Table S1
- Table S2

#### Additional information on study setting including clinic size

AHRI has operated a longitudinal population health and demographic surveillance system (HDSS) since 2003 in Hlabisa sub-district [1]. Individuals registered on the national ART programme database, TIER.Net, are retrospectively linked to the AHRI HDSS. However, we included all individuals aged ≥16 years registered on TIER.Net in the sub-district in our analysis, rather than only those who were linked to the HDSS. Since January 2017, the AHRI HDSS routinely offers point-of-care home-based HIV testing and counselling, and active linkage-to-care support with text message reminders and/or telephone calls up to 4 weeks after the HIV diagnosis [2]. Additionally, AHRI research nurses and research assistants are based at 11 of the 17 clinics to facilitate linkage to care and ART initiation. Research assistants register clinic attendance on an AHRI database (ClinicLink), and research nurses support DoH nursing staff to initiate ART under supervision of the clinic operational manager.

Clinicians and researchers of the Africa Health Research Institute (AHRI) supported rollout of antiretroviral therapy (ART) in the sub-district when ART first became available in the public sector, via the Hlabisa HIV Treatment and Care programme [3]. The HIV care programme was formally handed over to local Department of Health (DoH) staff in 2013. Based on this experience of working with local services, and a recent process evaluation of continuous quality improvement (CQI) at seven primary care clinics in the sub-district [4], most of the 17 nurse-led primary care clinics in Hlabisa sub-district, are in small single-storey buildings with limited space and limited staff. Resources are also limited, albeit to varying degrees in each clinic [4]. A key difference between these clinics is the number of patients seeking care (patient workload), a reflection of the local community size and accessibility by public transport. We therefore defined clinic size by ART patient workload over 12 months: small, ≤175 patients; medium, 176–374 patients; large, ≥375 patients.

Table S1. Number of women and men initiating ART by CD4-eligibility period and time period

Variable	Women					Men					Overall				
	Pre- Option B+	<b>Option B+</b> <i>n</i> =4245*		<b>UTT</b> <i>n</i> =4757*		Pre- Option B+ n=532*	Optio	ption B+ L		TT	Pre-Option B+	Option B+		UTT	
	n=1222*  Jul 2014 –  Dec 2014						n=2031*		n=2478*		n=1754*	n=6276*		n=7235*	
		Jan 2015 – Dec 2015	Jan 2016 – Aug 2016	Sep 2016 – Aug 2017	Sep 2017 – Mar 2019	Jul 2014 – Dec 2014	Jan 2015 – Dec 2015	Jan 2016 – Aug 2016	Sep 2016 – Aug 2017	Sep 2017 – Mar 2019	Jul 2014 – Dec 2014	Jan 2015 – Dec 2015	Jan 2016 – Aug 2016	Sep 2016 – Aug 2017	Sep 2017 – Mar 2019
	n=1222	n=2867	<i>n</i> =1378	n=2380	n=2377	n=532	<i>n</i> =1316	<i>n</i> =715	<i>n</i> =1111	<i>n</i> =1367	n=1754	n=4183	n=2093	<i>n</i> =3491	n=3744
Age (IQR)		-	-		-	-	-	-	-	-	-	-	=	_	-
	28	29	28	29	28	35	34	34	33	34	30	31	30	30	31
	(23–34)	(24–36)	(23–35)	(23–36)	(23–35)	(29-42)	(29–42)	(29–41)	(29–41)	(29–41)	(24–37)	(25–38)	(25–37)	(25–38)	(25–38)
Mean CD4,	cells/μL‡ (95%	CI)	_		_	-	_	_	_	_	_		-		
	332.2 (321.7– 342.7)	361.6 (355.5– 367.8)	356.7 (347.6– 365.7)	458.0 (449.5– 466.5)	432.0 (423.7– 440.3)	214.0 (203.3– 224.7)	243.4 (236.2– 250.6)	238.4 (229.0– 247.9)	339.8 (330.7– 348.9)	313.8 (305.3– 322.3)	296.9 (286.9– 307.0)	324.9 (319.3– 330.4)	317.1 (308.6– 325.6)	421.0 (413.0– 429.0)	389.5 (381.8– 397.1)
CD4 catego	ry, n (%)**														
≤100 cells/μL	134 (11.0%)	263 (9.2%)	144 (10.4%)	173 (7.3%)	189 (8.0%)	139 (26.1%)	283 (21.5%)	154 (21.5%)	197 (17.7%)	259 (19.0%)	273 (15.6%)	546 (13.1%)	298 (14.2%)	370 (10.6%)	448 (12.0%)
101- 200 cells/μL	178	339	205	223	258	133	241	173	191	270	311	580	378	414	528
	(14.6%)	(11.8%)	(14.9%)	(9.4%)	(10.9%)	(25.0%)	(18.3%)	(24.2%)	(17.2%)	(19.8%)	(17.7%)	(13.9%)	(18.1%)	(11.9%)	(14.1%)
201-350 cells/μL	496 (40.6%)	780 (27.2%)	368 (26.7%)	492 (20.7%)	561 (23.6%)	203 (38.2%)	395 (30.0%)	210 (29.4%)	278 (25.0%)	350 (25.6%)	699 (39.8%)	1175 (28.1%)	578 (27.6%)	770 (22.1%)	911 (24.3%)
351-500 cells/μL	200	1052	430	532	510	42	339	141	197	250	242	1391	571	729	760
	(16.4%)	(36.7%)	(31.2%)	(22.4%)	(21.5%)	(7.9%)	(25.8%)	(19.7%)	(17.7%)	(18.3%)	(13.8%)	(33.2%)	(27.3%)	(20.9%)	(20.3%)
>500 cells/μL	214 (17.5%)	433 (15.1%)	231 (16.8%)	960 (40.3%)	859 (36.1%)	15 (2.8%)	58 (4.4%)	37 (5.2%)	248 (22.3%)	238 (17.4%)	229 (13.1%)	491 (11.7%)	268 (12.8%)	1208 (34.6%)	1097 (29.3%)

<sup>\*</sup> sample sizes presented are for individuals with a CD4 count available within window

The distribution of missing CD4 counts over time is presented in Figure 2.

Table S2. Proportion without a CD4 within window among all ART initiators, by sex and clinic size at ART initiation

<sup>\*\*</sup> percentages may not add up to 100% due to rounding

<sup>&</sup>lt;sup>‡</sup> Generated using regression (interrupted time series) post-estimation commands.

Variable		Wo	men		Men				
Clinic size <sup>‡</sup> , number	Small	Medium	Large	Missing	Small	Medium	Large	Missing	
initiating ART	n=2040	<i>n</i> =5131	<i>n</i> =7120	n=7	n=827	n=2362	<i>n</i> =3110	n=2	
Total with no CD4 within window, n (%)*	218 (10.7%)	1101 (21.5%)	2752 (38.6%)	3	67 (8.1%)	347 (14.7%)	845 (27.2%)	1	
Age category, n (%)*									
16-25 years	99 (4.9%)	526 (10.3%)	1099 (15.4%)	1	6 (0.7%)	41 (1.7%)	81 (2.6%)	0	
26-35 years	87 (4.3%)	383 (7.5%)	1150 (16.2%)	2	28 (3.4%)	169 (7.2%)	396 (12.7%)	0	
36+ years	32 (1.6%)	192 (3.7%)	503 (7.1%)	0	33 (4.0%)	137 (5.8%)	368 (11.8%)	1	

<sup>\*</sup> Percentages may not add up to 100% due to rounding 
‡ Clinic size was determined by patient workload

#### References

- Tanser F, Hosegood V, Barnighausen T, et al. Cohort Profile: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey. Int J Epidemiol. 2008;37:956-62.
- Baisley KJ, Seeley J, Siedner MJ, et al. Findings from home-based HIV testing and facilitated linkage after scale-up of test and treat in rural South Africa: young people still missing. HIV Med. 2019;20:704-8.
- 3. Houlihan CF, Bland RM, Mutevedzi PC, et al. Cohort profile: Hlabisa HIV treatment and care programme. Int J Epidemiol. **2011**;40:318-26.
- 4. Yapa HM, Dhlomo-Mphatswe W, Moshabela M, et al. A continuous quality improvement intervention to improve antenatal HIV care testing in rural South Africa: evaluation of implementation in a real-world setting. Int J Health Policy Manag. 2020; Epub ahead of print.